News und Analysen
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6
Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results on Feb. 26
Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host
Agilent Automated Workflows at SLAS2025: Connecting with Confidence
Agilent Technologies Inc. (NYSE: A) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29
EQS-News: BB Biotech: Preliminary full-year 2024 results and dividend proposal
EQS-Adhoc: BB Biotech AG closes the 2024 fiscal year with a profit
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
EQS-News: Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
Novocure (NASDAQ: NVCR) announced today the official opening of its new global headquarters in the Canton of Zug, Switzerland. Novocure is an oncology company working to extend survival in some of
Novocure eröffnet neuen globalen Hauptsitz im Kanton Zug, Schweiz
Novocure (NASDAQ: NVCR) gab heute die offizielle Eröffnung seines neuen globalen Hauptsitzes im Kanton Zug, Schweiz, bekannt. Novocure ist ein Onkologieunternehmen, das daran arbeitet, durch die
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1
EQS-Adhoc: MEDICLIN raises full-year guidance for the 2024 financial year
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Apollo™ for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Premier, Inc. to Report Fiscal 2025 Second-Quarter Results and Host Conference Call on February 4, 2025
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 second quarter on Tuesday, February 4, 2025, at approximately 6:30 a.m. ET. The company will
Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced the integration of
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
EQS-News: Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
ICON Issues Financial Guidance for Full Year 2025
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the